Dr. Argiles on Study of Carcinoembryonic Antigen T-Cell Bispecific Antibody

Guillem Argiles, MD
Published Online: Wednesday, Jul 05, 2017



Guillem Argiles, MD, staff member, Gastrointestinal Malignancies Division, Vall d’Hebron University Hospital, discusses a carcinoembryonic antigen T-cell bispecific antibody.

In a study of patients with metastatic colorectal cancer, the novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody was evaluated as a monotherapy and in combination with atezolizumab (Tecentriq).

Results showed evidence of antitumor activity during dose escalation with CEA-TCB monotherapy, and a manageable safety profile was observed with the atezolizumab combination as well.
 


Guillem Argiles, MD, staff member, Gastrointestinal Malignancies Division, Vall d’Hebron University Hospital, discusses a carcinoembryonic antigen T-cell bispecific antibody.

In a study of patients with metastatic colorectal cancer, the novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody was evaluated as a monotherapy and in combination with atezolizumab (Tecentriq).

Results showed evidence of antitumor activity during dose escalation with CEA-TCB monotherapy, and a manageable safety profile was observed with the atezolizumab combination as well.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Optimizing Treatment and Management of Soft Tissue Sarcoma in Community OncologyNov 30, 20171.5
Community Practice Connections™: 1st Annual European Congress on Immunotherapies in Cancer™Dec 13, 20171.5
Publication Bottom Border
Border Publication
x